Business News • PR NewsWire • ThromboGenics Enrolls First Patients in Phase II Clinical Study Evaluating THR-317 (Anti-PlGF) for Diabetic Macular Edema (DME)

ThromboGenics Enrolls First Patients in Phase II Clinical Study Evaluating THR-317 (Anti-PlGF) for Diabetic Macular Edema (DME)

ThromboGenics Enrolls First Patients in Phase II Clinical Study Evaluating THR-317 (Anti-PlGF) for Diabetic Macular Edema (DME)

LEUVEN, Belgium, January 10, 2017 /PRNewswire/ -- THR-317 could become an attractive alternative or add-on treatment for current anti-VEGF medicines when treating DME or DR ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company, focused on...

View More : http://www.prnewswire.com/news-releases/thrombogenics-enrolls-first-patients-in-phase-ii-clinical-study-evaluating-thr-3...

Releted News by prnewswire

KDX shows off Glasses-free 3D Products at CES

Abilix Stuns CES, Introduces Revolutionary Educational Robots